{"id":"NCT01254422","sponsor":"Sanofi","briefTitle":"Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia","officialTitle":"Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12-02","primaryCompletion":"2012-09-28","completion":"2013-01","firstPosted":"2010-12-06","resultsPosted":"2019-07-29","lastUpdate":"2022-03-25"},"enrollment":250,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Dengue Fever","Dengue Hemorrhagic Fever"],"interventions":[{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus","otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Placebo: NaCl 0.9%","otherNames":["Saline"]}],"arms":[{"label":"CYD Dengue vaccine group","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia.\n\nPrimary Objectives:\n\n* To describe the safety (in terms of solicited and unsolicited adverse events) of the CYD dengue vaccine in all participants after each injection.\n* To describe the antibody response to each dengue virus serotype post-injection 2 and post-injection 3.","primaryOutcome":{"measure":"Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Vaccination With Either CYD Dengue Vaccine or a Placebo","timeFrame":"Day 0 up to Day 14 post-any and each vaccination","effectByArm":[{"arm":"CYD Dengue Vaccine Group","deltaMin":69.3,"sd":null},{"arm":"Placebo Group","deltaMin":56.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":4,"countries":["Malaysia"]},"refs":{"pmids":["24135573"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":199},"commonTop":["Injection site Pain; Post-Any","Malaise; Post-Any Injection","Headache; Post-Any Injection","Injection site Erythema; Post-Any","Asthenia; Post-Any Injection"]}}